Skip to content
DataLookout
Menu

NCT07739186

A Study Evaluating BL-B01D1 in Combination With a PD-1/VEGF Bispecific Antibody Versus Tislelizumab Plus Platinum-doublet Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer(PANKU-Lung06)

StatusRecruiting
PhasePhase 2/3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Recruitment opened
    • Start date changed from estimate of Nov 2026 to Oct 21, 2026
    • Site details revised at 2 of 2 sites
  2. Notable Start date: Aug 2026 to Nov 2026 Show 5 more changesShow less
    • Primary endpoint(s) modified
    • Eligibility criteria expanded, about 43 words
    • Enrollment increased: 120 → 166 participants
    • Interventions: BL-B01D1 (Drug), Carboplatin (Drug), Cisplatin (Drug), PD-1/VEGF Bispecific Antibody (Drug), Pemetrexed (Drug), Tislelizumab (Drug) to BL-B01D1 (Drug), Carboplatin (Drug), Cisplatin (Drug), PD-1/VEGF Bispecific Antibody (Drug), Pemetrexed (Drug), Tislelizumab (Drug)
    • Secondary endpoints revised (13)
  3. Minor Site contacts updated at 2 of 2 sitesv2
  4. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Phase II Part_A: Treatment Emergent Adverse Event (TEAE)
Timeframe: Up to approximately 24 months
Phase II Part_B: Objective Response Rate (ORR)
Timeframe: Up to approximately 24 months
Phase III: BICR-assessed Progression-free Survival (PFS)
Timeframe: Up to approximately 24 months
Phase III: Overall Survival (OS)
Timeframe: Up to approximately 24 months

Secondary (13)

Phase II/III: Objective Response Rate (ORR)
Phase II/III: Disease Control Rate (DCR)
Phase II/III: Duration of Response (DOR)
Phase II/III: Progression-free Survival (PFS)
Phase II Part_B/III: Treatment Emergent Adverse Event (TEAE)
Show 8 moreShow less
Phase II/III: Cmax
Phase II/III: Tmax
Phase II/III: T1/2
Phase II/III: AUC0-t
Phase II/III: CL (Clearance)
Phase II/III: Ctrough
Phase II/III: Anti-drug Antibody (ADA)
Phase III: Neutralizing Antibody(NAb)

Arms and interventions

BL-B01D1 + PD-1/VEGF Bispecific AntibodyExperimental

Participants receive BL-B01D1 + PD-1/VEGF Bispecific Antibody in the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.

PD-1/VEGF Bispecific Antibody + Pemetrexed + Carboplatin or CisplatinActive comparator

Participants receive PD-1/VEGF Bispecific Antibody + Pemetrexed + Carboplatin or Cisplatin in the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.

Tislelizumab + Pemetrexed + Carboplatin or CisplatinActive comparator

Participants receive Tislelizumab + Pemetrexed + Carboplatin or Cisplatin in the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.

Drugs: BL-B01D1, PD-1/VEGF Bispecific Antibody, Tislelizumab, Pemetrexed, Carboplatin, Cisplatin

Sites

2 sites in 1 country